Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Media
Activities
Datasets
Search by expertise, name or affiliation
The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
Jens U. Marquardt
, Anna Saborowski,
Carolin Czauderna
, Arndt Vogel
*
*
Corresponding author for this work
Clinic of Internal Medicine I
Hannover Medical School
13
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Immunotherapy
100%
Hepatocellular Carcinoma
100%
Systemic Therapy
100%
Sorafenib
100%
Tyrosine-Kinase Inhibitor
40%
Overall Survival
20%
Liver Function
20%
Immunoglobulin
20%
Combination Therapy
20%
Pembrolizumab
20%
Nivolumab
20%
Immune Checkpoint Inhibitor
20%
Ramucirumab
20%
Lenvatinib
20%
Regorafenib
20%
Monotherapy
20%
Cabozantinib
20%
Elevated Alpha-Fetoprotein
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Systemic Treatment
100%
Sorafenib
100%
Protein Tyrosine Kinase Inhibitor
40%
Alpha Fetoprotein
20%
Monotherapy
20%
Immune Checkpoint Inhibitor
20%
Cabozantinib
20%
Overall Survival
20%
Combination Therapy
20%
Immunoglobulin
20%
Pembrolizumab
20%
Lenvatinib
20%
Ramucirumab
20%
Regorafenib
20%